Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials

Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) being major risk factors. Despite advances in numerous therapy modalities, survival rates for HNSCC have not improved considerably...

Full description

Bibliographic Details
Main Authors:	Bharat Goel, Anoop Kumar Tiwari, Rajeev Kumar Pandey, Akhand Pratap Singh, Sujeet Kumar, Abhishek Sinha, Shreyans K. Jain, Arun Khattri
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	Translational Oncology
Subjects:	HNSCC Immunotherapy Clinical trial PD-1 EGFR Immune checkpoints
Online Access:	http://www.sciencedirect.com/science/article/pii/S1936523322000857

Similar Items

Low expression of TMPRSS2–a SARS-CoV-2 internalization protease–associates with basal subtype of head and neck squamous cell carcinoma
by: Jayesh Tiwari, et al.
Published: (2022-08-01)

Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
by: Bijan Khademi, et al.
Published: (2013-06-01)

Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response
by: Anne-Sophie Becker, et al.
Published: (2023-11-01)

Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma
by: Kimberly M. Burcher, et al.
Published: (2021-11-01)

Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma
by: Lauren C. J. Baker, et al.
Published: (2018-07-01)

Influence of EGF and pro-NGF on EGFR/SORTILIN interaction and clinical impact in head and neck squamous cell carcinoma
by: Martin Morisse, et al.
Published: (2023-07-01)

Survivin in Insulin-Like Growth Factor-Induced Resistance to Lapatinib in Head and Neck Squamous Carcinoma Cells
by: Christine E. Lehman, et al.
Published: (2019-01-01)

Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis
by: Leilei He, et al.
Published: (2019-02-01)

Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity
by: Kelvin Anderson, et al.
Published: (2021-02-01)

A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer
by: Henrik Schinke, et al.
Published: (2022-09-01)

Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
by: Christian Idel, et al.
Published: (2021-10-01)

Dynamic Up-Regulation of PD-L1 in the Progression of Oral Squamous Cell Carcinoma
by: Sonja Steen, et al.
Published: (2023-11-01)

Predictive Role of NEK6 in Prognosis and Immune Infiltration in Head and Neck Squamous Cell Carcinoma
by: Zhi-Min Yang, et al.
Published: (2022-07-01)

The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
by: Che-Wei Wang, et al.
Published: (2024-02-01)

Antitumor Efficacy of EGFR-Targeted Recombinant Immunotoxin in Human Head and Neck Squamous Cell Carcinoma
by: Guiqin Xie, et al.
Published: (2022-03-01)

The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
by: Marcos Paulo S. Damasio, et al.
Published: (2022-10-01)

The Immune Checkpoint Receptor CD96: A Local and Systemic Immune Modulator in Oral Cancer?
by: Leah Trumet, et al.
Published: (2023-04-01)

Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response
by: Sean P. Korpela, et al.
Published: (2021-01-01)

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
by: Alessio Cirillo, et al.
Published: (2024-04-01)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
by: Hannah Zaryouh, et al.
Published: (2022-12-01)

Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma
by: Bangrong Cao, et al.
Published: (2018-02-01)

PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols
by: Simona Crosta, et al.
Published: (2021-01-01)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
by: Julie E. Bauman, et al.
Published: (2020-06-01)

A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
by: Zeng Qi, et al.
Published: (2021-04-01)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
by: Juan L. Callejas-Valera, et al.
Published: (2022-05-01)

Case report: Patient specific combination of surgery and immunotherapy in advanced squamous cell carcinoma of the head and neck – a case series and review of literature
by: Manuel Olmos, et al.
Published: (2022-10-01)

Evaluation of the Targeting and Therapeutic Efficiency of Anti-EGFR Functionalised Nanoparticles in Head and Neck Cancer Cells for Use in NIR-II Optical Window
by: Teklu Egnuni, et al.
Published: (2021-10-01)

EGFR Mutation and 11q13 Amplification Are Potential Predictive Biomarkers for Immunotherapy in Head and Neck Squamous Cell Carcinoma
by: Shengjin Dou, et al.
Published: (2022-03-01)

The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
by: Hannah Zaryouh, et al.
Published: (2021-09-01)

Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells
by: Sebastian Wimmer, et al.
Published: (2021-08-01)

Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
by: Andrew Meci, et al.
Published: (2024-02-01)

Neuropilin-1 Expression Associates with Poor Prognosis in HNSCC and Elicits EGFR Activation upon CDDP-Induced Cytotoxic Stress
by: Virginia Napolitano, et al.
Published: (2021-07-01)

PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection
by: Fan Yang, et al.
Published: (2018-12-01)

Research Progress of Ferroptosis in Head and Neck Squamous Cell Carcinoma
by: XIE Zhanghong, et al.
Published: (2022-04-01)

5ʹ-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells
by: Enxian Shi, et al.
Published: (2023-08-01)

EGFR/PI3K/Akt/mTOR pathway in head and neck squamous cell carcinoma patients with different HPV status
by: Anna Janecka-Widła, et al.
Published: (2022-02-01)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
by: Victor C. Kok, et al.
Published: (2020-02-01)

HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines
by: Maria Paula Gomez Hernandez, et al.
Published: (2019-09-01)

Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma
by: Lilan Yi, et al.
Published: (2020-09-01)

Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
by: Bijan Khademi, et al.
Published: (2013-06-01)